DOP2016000176A - Insulina de acción prolongada y uso de la misma - Google Patents

Insulina de acción prolongada y uso de la misma

Info

Publication number
DOP2016000176A
DOP2016000176A DO2016000176A DO2016000176A DOP2016000176A DO P2016000176 A DOP2016000176 A DO P2016000176A DO 2016000176 A DO2016000176 A DO 2016000176A DO 2016000176 A DO2016000176 A DO 2016000176A DO P2016000176 A DOP2016000176 A DO P2016000176A
Authority
DO
Dominican Republic
Prior art keywords
insulin
same
prolonged action
prolonged
action
Prior art date
Application number
DO2016000176A
Other languages
English (en)
Inventor
Sung Youb Jung
Sang Youn Hwang
Euh Lim Oh
Sung Hee Park
Hyun Uk Kim
Chang Ki Lim
Se Chang Kwon
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of DOP2016000176A publication Critical patent/DOP2016000176A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UN ANÁLOGO DE INSULINA QUE PRESENTA UNA AFINIDAD REDUCIDA DE LA UNIÓN AL RECEPTOR DE INSULINA CON EL PROPÓSITO DE AUMENTAR LA VIDA MEDIA EN SANGRE DE LA INSULINA, Y A UNA INSULINA DE ACCIÓN PROLONGADA, A UN CONJUGADO, Y A UN MÉTODO DE PREPARACIÓN DE UNA INSULINA DE ACCIÓN PROLONGADA QUE LA UTILICE.
DO2016000176A 2014-01-20 2016-07-14 Insulina de acción prolongada y uso de la misma DOP2016000176A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20140006938 2014-01-20

Publications (1)

Publication Number Publication Date
DOP2016000176A true DOP2016000176A (es) 2017-02-15

Family

ID=53543214

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000176A DOP2016000176A (es) 2014-01-20 2016-07-14 Insulina de acción prolongada y uso de la misma

Country Status (22)

Country Link
US (1) US10253082B2 (es)
EP (1) EP3098235A4 (es)
JP (1) JP2017505141A (es)
KR (1) KR102406654B1 (es)
CN (2) CN116987172A (es)
AU (1) AU2015206890B2 (es)
BR (1) BR112016016578A2 (es)
CA (1) CA2937168A1 (es)
CL (1) CL2016001844A1 (es)
CR (1) CR20160376A (es)
DO (1) DOP2016000176A (es)
EA (1) EA201691374A1 (es)
EC (1) ECSP16068524A (es)
IL (1) IL246782B (es)
MA (3) MA46146A1 (es)
MX (1) MX369656B (es)
MY (1) MY186251A (es)
PE (1) PE20161153A1 (es)
PH (1) PH12016501414B1 (es)
SG (1) SG11201605680PA (es)
WO (1) WO2015108398A1 (es)
ZA (1) ZA201605626B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016009465A (es) 2014-01-20 2016-12-02 Cleave Biosciences Inc Pirimidinas fusionadas como inhibidores del complejo p97.
CN108064173B (zh) 2014-11-21 2021-05-18 默沙东公司 胰岛素受体部分激动剂
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
UY36870A (es) * 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
KR20170036643A (ko) * 2015-09-24 2017-04-03 한미약품 주식회사 인슐린의 제조 방법
AU2017332408B2 (en) * 2016-09-23 2022-02-10 Hanmi Pharm. Co., Ltd. Insulin analogs with reduced affinity to insulin receptor and use thereof
BR112019016077A2 (pt) 2017-02-03 2020-03-31 Hanmi Pharm. Co., Ltd. Conjugado da fórmula 1, método para preparar o conjugado, preparação de atuação longa, preparação para prevenir ou tratar diabetes e método para tratar diabetes
EP3604328A4 (en) * 2017-03-23 2021-01-06 Hanmi Pharm. Co., Ltd. REDUCED INSULIN ANALOGUE COMPLEX FOR INSULIN RECEPTOR AND ITS USE
CN111406073A (zh) * 2017-09-29 2020-07-10 韩美药品株式会社 具有提高功效的持久性蛋白质缀合物
KR102666154B1 (ko) * 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
KR102646845B1 (ko) * 2018-08-08 2024-03-14 주식회사 대웅제약 클로스트리파인을 이용한 지속형 인슐린 아날로그 복합체의 활성형 제조방법
WO2020120479A1 (en) 2018-12-11 2020-06-18 Sanofi Peptide binder
CN114174348A (zh) * 2019-07-31 2022-03-11 伊莱利利公司 胰岛素类似物及其使用方法
US11746137B2 (en) * 2020-03-31 2023-09-05 Hanmi Pharm. Co., Ltd. Immunostimulating IL-2 analogs

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175145A (en) 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
US5422339A (en) * 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP1141014B1 (en) 1999-01-06 2004-12-08 Genentech, Inc. Insulin-like growth factor (igf) i mutant variant
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
CA2518776A1 (en) 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
WO2005012346A1 (en) 2003-07-25 2005-02-10 Conjuchem, Inc. Long lasting insulin derivatives and methods thereof
AU2004282984B2 (en) 2003-11-13 2011-07-14 Hanmi Science Co., Ltd. Protein complex using immunoglobulin fragment andmethod for the preparation thereof
WO2007020256A1 (en) 2005-08-16 2007-02-22 Novo Nordisk A/S Method for making mature insulin polypeptides
JP5550338B2 (ja) * 2006-07-31 2014-07-16 ノボ・ノルデイスク・エー／エス ペグ化持続型インスリン
WO2008049711A1 (en) * 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
US7790677B2 (en) 2006-12-13 2010-09-07 Elona Biotechnologies Insulin production methods and pro-insulin constructs
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
EP2017288A1 (en) 2007-07-16 2009-01-21 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
CN101743252A (zh) * 2007-07-16 2010-06-16 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、peg化的胰岛素类似物
ES2548304T3 (es) 2007-08-15 2015-10-15 Novo Nordisk A/S Análogos de la insulina que contienen una fracción acilo y alquilenglicol
PT2597103T (pt) 2007-11-16 2017-02-08 Novo Nordisk As Composições farmacêuticas contendo insulina e um péptido insulinotrófico
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
RU2524423C2 (ru) 2008-01-09 2014-07-27 Санофи-Авентис Дойчланд Гмбх Новые производные инсулина с чрезвычайно замедленным профилем время/действие
AU2009203810B2 (en) 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
WO2009112583A2 (en) * 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
PL2254906T3 (pl) 2008-03-18 2017-04-28 Novo Nordisk A/S Stabilizowane względem proteaz, acylowane analogi insuliny
WO2009129250A2 (en) 2008-04-14 2009-10-22 Case Western Reserve University Meal-time insulin analogues of enhanced stability
CA2740685C (en) 2008-10-17 2018-09-11 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a glp-1 agonist
CN102245624B (zh) * 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
EP2376520B1 (en) 2008-12-19 2014-02-12 Indiana University Research&Technology Corporation Insulin analogs
WO2010108937A2 (en) 2009-03-27 2010-09-30 Glaxo Group Limited Drug fusions and conjugates
US20120184488A1 (en) 2009-09-01 2012-07-19 Case Western Reserve University Insulin analogues of enhanced receptor-binding specificity
KR101058209B1 (ko) 2009-12-30 2011-08-22 전자부품연구원 Ｏｆｄｍ 방식의 디지털 방송 시스템의 빠른 동기 방법
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101330868B1 (ko) * 2010-06-08 2013-11-18 한미사이언스 주식회사 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체
KR101324828B1 (ko) 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
JP5969469B2 (ja) * 2010-06-16 2016-08-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
EP2598527A4 (en) 2010-07-28 2014-01-08 Smartcells Inc RECOMBINANT EXPRESSED INSULIN POLYPEPTIDES AND APPLICATIONS THEREOF
WO2012098462A1 (en) 2011-01-20 2012-07-26 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
EP2681346B1 (en) 2011-03-02 2017-09-06 Oerlikon Surface Solutions AG, Pfäffikon Sliding component coated with metal-comprising carbon layer for improving wear and friction behavior by tribological applications under lubricated conditions
CN102675452B (zh) 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
CN103582801B (zh) 2011-05-03 2015-11-25 帝人芳纶有限公司 防弹板
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
CA2837710C (en) 2011-06-02 2022-11-08 Prolor Biotech Inc. Pegylated oxyntomodulin conjugates with improved linkers
DK2718318T3 (en) 2011-06-10 2018-11-05 Hanmi Science Co Ltd New oxyntomodulin derivatives and pharmaceutical compositions for the treatment of obesity comprising these
ES2882520T3 (es) 2011-06-17 2021-12-02 Hanmi Science Co Ltd Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina y su uso
WO2013089463A1 (en) 2011-12-16 2013-06-20 Lg Innotek Co., Ltd. Method for deposition of silicon carbide and silicon carbide epitaxial wafer
US20150299286A1 (en) 2012-01-20 2015-10-22 Case Western Reserve University Glutamic acid-stabilized insulin analogues
KR101665009B1 (ko) 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
UA126651C2 (uk) 2012-11-06 2023-01-11 Ханмі Фарм. Ко., Лтд. Рідка композиція протеїнового кон'югата, що містить оксинтомодулін та фрагмент імуноглобуліну
ES2868351T3 (es) * 2013-02-26 2021-10-21 Hanmi Pharm Ind Co Ltd Conjugados de análogos de insulina y usos de los mismos
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
KR101676542B1 (ko) 2014-12-30 2016-11-16 건국대학교 산학협력단 프로인슐린의 면역학적 용도

Also Published As

Publication number Publication date
CN105916877A (zh) 2016-08-31
CN116987172A (zh) 2023-11-03
ECSP16068524A (es) 2018-11-30
PH12016501414A1 (en) 2016-09-14
WO2015108398A1 (ko) 2015-07-23
EA201691374A1 (ru) 2016-12-30
PE20161153A1 (es) 2016-10-27
JP2017505141A (ja) 2017-02-16
US10253082B2 (en) 2019-04-09
MA39301A1 (fr) 2018-01-31
MA46146A1 (fr) 2020-12-31
MX2016009434A (es) 2017-01-18
KR102406654B1 (ko) 2022-06-10
KR20150087130A (ko) 2015-07-29
AU2015206890B2 (en) 2019-05-23
CR20160376A (es) 2016-10-07
IL246782A0 (en) 2016-08-31
MY186251A (en) 2021-06-30
EP3098235A1 (en) 2016-11-30
ZA201605626B (en) 2017-11-29
BR112016016578A2 (pt) 2017-10-03
MX369656B (es) 2019-11-15
MA43289B1 (fr) 2019-12-31
PH12016501414B1 (en) 2016-09-14
AU2015206890A1 (en) 2016-08-04
IL246782B (en) 2020-01-30
US20170101455A1 (en) 2017-04-13
CA2937168A1 (en) 2015-07-23
EP3098235A4 (en) 2017-10-18
SG11201605680PA (en) 2016-09-29
CL2016001844A1 (es) 2017-01-06

Similar Documents

Publication Publication Date Title
DOP2016000176A (es) Insulina de acción prolongada y uso de la misma
MX2020014121A (es) Agonistas parciales del receptor de insulina.
CO7151531A2 (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
PH12016501618A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
DOP2016000315A (es) Anticuerpos monoclonales contra el epítope de her2 y sus métodos de uso
CL2015002330A1 (es) Análogo de insulina novedoso y su uso.
CL2016002772A1 (es) Composiciones de insulina de rápida acción
ES2681973T3 (es) Respuesta antitumoral contra autoepítopos modificados
TWD170335S (zh) 錶
TWD170341S (zh) 手錶
TWD170026S (zh) 容器
MX354303B (es) Anticuerpos de anti-biotina y metodos de uso.
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
CL2016002223A1 (es) Microorganismo recombinante que expresa análogos de avermectina y uso de los mismos.
PH12017500052A1 (en) Myo-inositol and probiotics and uses
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
MY180166A (en) Cosmic quenchers
TR201902547T4 (tr) Oksi̇dati̇f stresli̇ hastalarda parati̇roi̇d hormonunun ölçüm araçlari ve yöntemleri̇
EP3606579A4 (en) INJECTOR WITH READY FOR USE INDICATOR
PH12017500084A1 (en) Vitamin b2 and its use
MX2016013979A (es) Nuevas vias de administracion de insulina, analogos de insulina o derivados de insulina.
UA92234U (ru) Применение лактопротеина с сорбитолом как маркера изменений проницаемости кровеносных капилляров внутренних органов при ожоговой болезни